References
- Parkin D. M., Laara E., Muir C. S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 1988; 41: 184–197, [PUBMED], [INFOTRIEVE]
- Landis S. H., Murray T., Bolden S., et al. Cancer statistics, 1998. CA Cancer J. Clin. 1998; 48: 6–29, [PUBMED], [INFOTRIEVE], [CSA]
- Micke O., Prott F. J., Schaffer U., et al. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000; 20: 5113–5116, [PUBMED], [INFOTRIEVE], [CSA]
- Rose P. G., Baker S., Fournier L., et al. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. Am. J. Obstet. Gynecol. 1993; 168: 942–946, [PUBMED], [INFOTRIEVE]
- Yazigi R., Munoz A. K., Richardson R., et al. Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer. Gynecol. Oncol. 1991; 41: 135–138, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Scambia G., Benedetti P., Foti E., et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J. Clin. Oncol. 1994; 12: 2309–2316, [PUBMED], [INFOTRIEVE]
- Micke O. Der Stellenwert von Tumormarkern in der Radioonkologie. Diplodocus-Verlag, Altenberge, in press
- Pohl A. L. Surveillance of cancer patients with tumor markers. J. Tumor Marker Oncol. 1987; 2: 1–14
- Torre G. C. SCC antigen in malignant and nonmalignant squamous lesions. Tumor Biol. 1988; 19: 517–526, [CSA], [CROSSREF]
- Goldberg M. A., Lee M. J., Fischman A. J., et al. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. Radiographics 1993; 13: 1047–1062, [PUBMED], [INFOTRIEVE], [CSA]
- Shields A. F., Graham M. M., Spence A. M. The role of PET imaging in clinical oncology: a current status report. Nuclear Medicine Annual, L. M. Freeman. Raven Press, New York 1995; 129–168
- Gambhir S. S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG-PET literature. J. Nucl. Med. 2001; 42: 1S–93S, [PUBMED], [INFOTRIEVE]
- Shepherd J. H. Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol. 1989; 96: 889–892, [PUBMED], [INFOTRIEVE]
- Leisure G. P., Vesselle H. J., Faulhaber P. F., et al. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J. Nucl. Med. Technol. 1997; 25: 115–119, [PUBMED], [INFOTRIEVE], [CSA]
- ABBOTT SCC RIABEAD insert. ABBOTT Diagnostics Division: July 1997
- Willson J. R. Malignant cervical lesions. Obstetrics and Gynecology7th Ed., J. R. Willson. CV Mosby Co., St. Louis 1983; 622–629
- Peeples W. J., Inalsingh C. H., Hazra T. A., et al. The occurrence of metastasis outside the abdomen and retroperitoneal space in invasive carcinoma of the cervix. Gynecol. Oncol. 1976; 4: 307–310, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hricak H., Yu K. K. Radiology in invasive cervical cancer. Am. J. Roentgenol. 1996; 167: 1101–1108, [CSA]
- Yu K. K., Forstner R., Hricak H. Cervical carcinoma: role of imaging. Abdom. Imaging 1997; 22: 208–215, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Scheidler J., Hricak H., Yu K. K., et al. Radiological evaluation of lymph node metastases in patients with cervical cancer: a metaanalysis. JAMA 1997; 278: 1096–1101, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sun S. S., Chen T. C., Yen R. F., et al. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res. 2001; 21: 2957–2962, [PUBMED], [INFOTRIEVE], [CSA]